Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
Editas Medicine
ISIN US28106W1036
|WKN A2AC4K
Market cap (in EUR)
268 m
Country
Verenigde Staten
Sector
Gezondheidszorg
Dividend yield
0,00%
Overview
Description
Editas Medicine, Inc. houdt zich bezig met de ontwikkeling en commercialisering van genoombewerkingstechnologie. De technologie omvat CRISPR (clustered, regularly interspaced short palindromic repeats) en Cas9 (CRISPR associated protein 9). Het bedrijf werd in september 2013 opgericht door Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung en David R. Liu en heeft zijn hoofdkantoor in Cambridge, MA.
Gezondheidszorg Biofarmaceutica Niet-Systeemspecifieke Biofarmaceutica Verenigde Staten
Financials
Key metrics
| Market capitalisation, EUR | 268 m |
| EPS, EUR | -1,67 |
| P/B ratio | 11,5 |
| P/E ratio | - |
| Dividend yield | 0,00% |
Income statement (2025)
| Revenue, EUR | 36 m |
| Net income, EUR | -142 m |
| Profit margin | -395,01% |
What ETF is Editas Medicine in?
There is 1 ETF which contains Editas Medicine.
| ETF | Weight | Investment focus | Fund size (in m EUR) |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 0,02% | Equity United States Health Care Biotech | 46 |
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.